ENDOLOGIX INC /DE/ - FORM 10-Q - XML - IDEA: XBRL DOCUMENT - August 3, 2011



Attached files
FileFilename
EXCEL - IDEA: XBRL DOCUMENT - ENDOLOGIX INC /DE/Financial_Report.xls
10-Q - FORM 10-Q - ENDOLOGIX INC /DE/elgx-2011630x10q.htm
XML - IDEA: XBRL DOCUMENT - ENDOLOGIX INC /DE/R4.htm
XML - IDEA: XBRL DOCUMENT - ENDOLOGIX INC /DE/R1.htm
XML - IDEA: XBRL DOCUMENT - ENDOLOGIX INC /DE/R9.htm
XML - IDEA: XBRL DOCUMENT - ENDOLOGIX INC /DE/R2.htm
XML - IDEA: XBRL DOCUMENT - ENDOLOGIX INC /DE/R8.htm
XML - IDEA: XBRL DOCUMENT - ENDOLOGIX INC /DE/R5.htm
XML - IDEA: XBRL DOCUMENT - ENDOLOGIX INC /DE/R6.htm
XML - IDEA: XBRL DOCUMENT - ENDOLOGIX INC /DE/R3.htm
XML - IDEA: XBRL DOCUMENT - ENDOLOGIX INC /DE/R10.htm
XML - IDEA: XBRL DOCUMENT - ENDOLOGIX INC /DE/R15.htm
XML - IDEA: XBRL DOCUMENT - ENDOLOGIX INC /DE/R14.htm
XML - IDEA: XBRL DOCUMENT - ENDOLOGIX INC /DE/R12.htm
XML - IDEA: XBRL DOCUMENT - ENDOLOGIX INC /DE/R11.htm
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER - ENDOLOGIX INC /DE/elgx-ex312_2011630q2.htm
EX-32.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER - ENDOLOGIX INC /DE/elgx-ex321_2011630xq2.htm
EX-32.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER - ENDOLOGIX INC /DE/elgx-ex322_2011630xq2.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER - ENDOLOGIX INC /DE/elgx-ex311_2011630xq2.htm
XML - IDEA: XBRL DOCUMENT - ENDOLOGIX INC /DE/R13.htm
v2.3.0.11
Stock-Based Compensation
6 Months Ended
Jun. 30, 2011
Stock Based Compensation [Abstract]  
Stock-based Compensation
Stock-Based Compensation


The Company values stock-based awards, including stock options and restricted stock, as of the date of grant. The Company uses the Black-Scholes option-pricing model in valuing granted stock options. The fair value of granted restricted stock awards is equal to the Company's closing stock price on the date of grant. The Company recognizes stock-based compensation expense, net of estimated forfeitures, using the straight-line method over the requisite service period. Forfeitures are estimated at the time of grant, and prospectively revised if actual forfeitures differ from those estimates. The Company classifies compensation expense related to these awards in the Condensed Consolidated Statements of Operations, based on the department to which the recipient reports.
Stock-based compensation expense included in cost of revenue and operating expenses during the three and six months ended June 30, 2011 and 2010 was as follows:
 
Three  Months Ended
 
Six Months Ended
 
June 30,

2011
 
June 30,

2010
 
June 30,

2011
 
June 30,

2010
Cost of goods sold


 
39


 
40


 
98


Marketing and sales
445


 
298


 
851


 
534


Research and development
277


 
63


 
415


 
111


Clinical and regulatory affairs
35


 
25


 
61


 
47


General and administrative
329


 
318


 
517


 
678


Total
$
1,086


 
$
743


 
$
1,884


 
$
1,468


User Contributions:

Comment about this document or add new information about this topic:

CAPTCHA



This web site and associated pages are not associated with, endorsed by, or sponsored by ENDOLOGIX INC /DE/ and has no official or unofficial affiliation with ENDOLOGIX INC /DE/


Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site.  Use at your own risk. This website is not associated with the SEC

Some parts © 2013 Advameg, Inc.